Chlamydia species cause a broad spectrum of diseases in humans including severe chronic sequelae related to persistent forms. Despite the lack of detectable amounts of peptidoglycan, several studies suggest the presence of small quantities of peptidoglycan or its derivative at least in some stages of the growth cycle. Based on recent discovery in Chlamydiae ofthe aminotransferase pathway for biosynthesis of meso-diaminopimelic acid, we demonstrated the up-regulation of the gene (cp0259) encoding L,L-diaminopimelate aminotransferase in chlamydial persistent forms. This finding may be important in the search for target molecules to diagnose and treat Chlamydia-associated chronic diseases.
Chlamydiae
are Gram-negative bacteria that share many biological characteristics. For example, Chlamydia species are obligate intracellular microorganisms and undergo a biphasic developmental cycle, alternating between infectious elementary bodies (EBs) and replicative reticulate bodies (RBs). More recently a third nonreplicating, non-infectious and metabolically altered form, called persistent form, has been described (I). Morphologically, Chlamydiae lack detectable peptidoglycan (PG) and the structural integrity ofthe cell envelope appears to be provided by a network of disulfide cross-linked proteins associated with the outer membrane.
Despite such common characteristics Chlamydiae cause a broad spectrum of diseases in humans. Chlamydia trachomatis is the leading cause of bacterial sexually transmitted diseases in developed countries and of trachoma in developing nations; Chlamydophila pneumoniae causes communityacquired pneumonia and other respiratory tract infections; Chlamydophila psittaci is the causative agent of psittacosis, a zoonotic pneumonia. More importantly, these pathogens cause chronic sequelae. In fact, C. trachomatis infections lead to pelvic inflammatory disease, obstructive infertility, and reactive arthritis, and its involvement has been suggested in the pathogenesis of chronic intestinal diseases (2); C. pneumoniae infection has been implicated in atherosclerosis (3-I6) and more recently in osteoporosis-associated bone loss (17); C. psittaci infection has been associated with ocular adnexal mucosa-associated lymphoid tissue (MALT) (18) . These pathological sequelae have been proposed to result from the inflammatory state induced by chlamydial persistent forms that are inherently more suited to evade the host immune response and are difficult to eradicate with antibiotics.
Currently there are no reliable methods for diagnosis of chronic infections nor are there any drugs effective against such chlamydial infections. Many in vitro studies have described the development of chlamydial persistent forms after exposure to penicillin, thus suggesting a predominant role of PG in RB development. Indeed, it is well documented that penicillin typically acts by blocking PG biosynthesis through interaction with penicillin binding proteins. Therefore antibiotic-induced persistence is particularly important since unsuitable antimicrobial therapy may allow Chlamydiae to persist in vivo leading to the development of chronic diseases.
Consequently, there is an urgent need to identify markers of chronic infection and potential drug targets for all medically significant species of Chlamydia. For example, investigations on the unusual chlamydial cell wall could be useful to better understand the interaction between these microorganisms and the host. Although Chlamydiae do not synthesize PG, genome sequencing has revealed that these pathogens appear to contain a nearly complete set of genes encoding the enzymes for PG biosynthesis (19, 20) , several of which are known to be expressed during the growth cycle. However, the PG biosynthetic pathway does not seem to be complete and several enzymes such as glycosyltransferases, required for the construction of the linear glycan chains (21) , are missing.
To date two hypotheses regarding the presence of an unusual cell wall in Chlamydiae have been proposed. The first proposes that Chlamydiae synthesize PG strictly during cell division. In support of this idea, Brown and Rockey (22) isolated antibodies, directed against a non-proteinaceous antigen, called SEP (septum), that recognized an apparent division septum of Chlamydiae. In particular, these antibodies localize to a ringlike structure within or between developing RBs, reminiscent of FtsZ rings observed in most bacteria, whereas for example in E. coli the bacteria locate on the entire cell wall, suggesting a structural affinity to the usual PG-containing cell wall.
The second even more intriguing hypothesis suggests that fragments of PG, called muropeptides, are delivered into the host cell cytosol and are recognized by the host innate immune system. Consistent with this hypothesis, several studies (23, 24) have demonstrated the recognition of intracellular Chlamydiae by NodI (nucleotide binding oligomerization domain protein), a cytosolic receptor that has the ability to detect meso-diaminopimelic acid (m-DAP) containing fragments of PG and to activate the secretion of proinflammatory cytokines.
Chlamydiae, like certain pathogenic bacteria, may employ the type III secretion system to translocate muropeptides directly into host cell cytosol and trigger an inflammatory response. Regarding m-DAP, this plays a pivotal role in PG biosynthesis by cross-linking PG glycan chains to provide strength and rigidity. Interestingly, a recent study revealed that an aminotransferase pathway for m-DAP biosynthesis exists in Chlamydiae (25) . In particular, the ct390 gene from C. trachomatis was shown to encode the L,L-diaminopimelate aminotransferase (L,L-DAP-AT) that convert tetrahydrodipicolinate to L,L-diaminopimelic acid, the precursor of m-DAP. Biochemical characterization and crystal structure of C. trachomatis L,L-DAP-AT have recently been reported (26) .
In this context, we obtained a relevant result by using the in vitro model of penicillin G-mediated persistence in C. pneumoniae (27) since this persistence model is directly linked to the PG biosynthesis and also simulates treatment failure of chronic infection in vivo. Notably the cp0259 gene of C. pneumoniae, homologous of the ct390 gene of C. trachomatis, is up-regulated ( Fig. I) during penicillin-induced persistence, although some authors did not find significant up-regulation with other persistence inducers such as iron depletion and interferon-y (28, 29) . Taking into account the considerations made above, we can suppose that the physiological significance of this up-regulation, probably aimed to counteract the effects of the penicillin G, may be in relation to the release of muropeptides involved in the host inflammatory response. In fact, the main feature of the chronicinflammatory diseases related to Chlamydiae is the remarkable tissue damage mediated by the induced host response.
Although further studies are needed to characterize the role of m-DAP in the physiology and the pathogenesis of Chlamydiae, the discovery of the aminotransferase pathway for m-DAP biosynthesis and the analysis of the expression profile of the genes involved may be important in the search for target molecules to diagnose and treat Chlamydia-associated chronic diseases.
